The transcription factor Nrf2 coordinates an adaptive response to chemical and oxidative stress characterised by the upregulated expression of cytoprotective target genes. In order to understand the mechanistic relevance of Nrf2 as a marker of drug-induced stress it is important to know if this adaptive response is truly localised in the context of organ-specific drug toxicity. Here, we address this knowledge gap through real-time bioluminescence imaging of transgenic Nrf2-luciferase (Nrf2-luc) reporter mice following administration of the metabolism-dependent hepatotoxin acetaminophen (APAP) or the direct nephrotoxin cisplatin. We detected localised bioluminescence in the liver (APAP) and kidneys (cisplatin) in vivo and ex vivo, whilst qPCR, Taqman low-density array and immunoblot analysis of these tissues further revealed increases in the expression level of several endogenous Nrf2-regulated genes/proteins, including heme oxygenase 1 (Hmox1). Consistent with the toxic effects of APAP in the liver and cisplatin in the kidney, immunohistochemical analysis revealed the elevated expression of luciferase and Hmox1 in centrilobular hepatocytes and in tubular epithelial cells, respectively. In keeping with the role of reactive metabolite formation in APAP-induced chemical stress, both the hepatotoxicity and localised Nrf2-luc response were ameliorated by the cytochrome P450 inhibitor aminobenzotriazole. Together, these findings show that Nrf2 can reflect highly-localised cellular perturbations associated with relevant toxicological mechanisms.
Drug toxicity is an impediment to the development of urgently-needed new medicines and causes major clinical complications, often resulting in the post-marketing withdrawal of otherwise effective therapeutic agents1. Therefore, innovative strategies are required to improve the pre-clinical detection of drug candidates that pose a risk to patients. One emerging approach, inspired by a landmark report from the National Research Council2, involves assessing the ability of a compound to trigger one or more stress response pathways that can reflect cellular perturbations linked to a critical endpoint. Such an approach has inspired several projects (e.g. the Tox21 initiative3) which aim to screen large libraries of chemical entities in human cell lines equipped with reporters for major stress responses or other relevant biological pathways, with a view to identifying signatures that are reflective of certain toxicity mechanisms. In the context of drug toxicity, relevant stress responses include those triggered by DNA damage, endoplasmic reticulum stress, inflammation and chemical/oxidative stress4.
In mammalian cells the major regulator of the adaptive response to chemical/oxidative stress is the transcription factor Nuclear factor erythroid 2-related factor 2 (Nrf2)5. Under physiological conditions, Nrf2 binds to Kelch-like ECH-associated protein-1 (Keap1) in the cytoplasm, leading to its ubiquitination and proteasomal degradation. Under conditions of chemical and oxidative stress, however, the interaction between Nrf2 and Keap1 is disrupted, resulting in the accumulation of the former in the nucleus, where it interacts with antioxidant response elements (AREs) and promotes the expression of target genes including Heme oxygenase 1 (Hmox1), Sulfiredoxin 1 (Srxn1) and NAD(P)H dehydrogenase [quinone] 1 (Nqo1). Consistent with this, genetic disruption of the Nrf2 gene lowers the expression of an array of cytoprotective genes6,7 and renders mice more sensitive to the adverse effects of many toxic compounds8.
Activation of Nrf2 signalling has been demonstrated in animals exposed to many drugs and chemical entities9, yet such in vivo studies have almost exclusively relied on the analysis of a single tissue relevant to the toxicological insult (e.g. our previous work showing activation of Nrf2 in the livers of mice exposed to the hepatotoxin acetaminophen10). However, to fully understand the ability of Nrf2 to reflect the organ-specific perturbations that typically underlie drug toxicities, it is necessary to assess the response of the pathway in non-target tissues. In particular, such knowledge will inform the reliability of extrapolating findings in cell-based reporter assays into a whole body, in vivo context. We previously generated transgenic mice (hereafter referred to as Nrf2-luc mice) expressing the OKD48 reporter, which enables real-time monitoring of the Nrf2-driven response to chemical/oxidative stress11. The reporter comprises a transcriptionally inactive luciferase-tagged Nrf2 which is under the transcriptional control of endogenous Nrf2 and subject to post-transcriptional regulation by Keap111. We showed that a bioluminescent signal could be detected throughout the body following exposure to the general oxidative stressors sodium arsenite and ultraviolet radiation11. Here, in order to assess the ability of Nrf2 to reflect organ-specific perturbations, we have used real-time bioluminescence imaging of Nrf2-luc mice to reveal localised Nrf2-driven stress responses to drug-induced toxicity.
Acetaminophen activates hepatic Nrf2 signalling in vivo
Our previous work has shown that acetaminophen (APAP) activates Nrf2 signalling in the livers of CD-1 mice10. As the transgenic Nrf2-luc mice are of a C57Bl/6 J background, we sought to confirm our earlier findings and establish hepatotoxic conditions in wild type mice of the same strain prior to undertaking bioluminescent imaging studies. Male C57BL/6 J mice were therefore administered 300 mg/kg APAP and culled after 0, 2, 6, 24 or 48 h. Hepatic glutathione (GSH) content was significantly decreased 2 h after APAP administration, followed by a time-dependent rebound (Fig. 1A). Consistent with the rapid and substantial depletion of GSH in the liver, serum alanine aminotransferase (ALT) levels were significantly higher at 2, 6 and 24 h in mice treated with APAP, with recovery evident at 48 h (Fig. 1B). We next assessed the activity of the Nrf2 pathway in the livers of the mice, by quantifying the mRNA expression levels of known target genes. APAP provoked significant increases in the expression of Hmox1, Gsta1, Srxn1 and Nqo1, with variable magnitudes and time-dependence of response evident across the four genes (Fig. 1C). The substantial early increases in Hmox1 mRNA were associated with significant increases in the hepatic protein level of Hmox1 at 6, 24 and 48 h following APAP administration (Fig. 1D,E), whereas the relatively smaller changes in Nqo1 mRNA were not associated with a significant increase in its protein level (Fig. 1D,E). Together, these data confirm that a hepatotoxic dose of APAP activates Nrf2 signalling in the livers of C57Bl/6 J mice.
Characterisation of Nrf2-luc mice
In order to ensure that the Nrf2-luc transgene did not alter the basal level of GSH and expression of Nrf2 target genes, we compared these traits in the livers of naïve wild type C57Bl/6 J and Nrf2-luc mice. For both female and male mice, there was no significant difference in hepatic GSH content between the two strains (Fig. S1A). In addition, introduction of the Nrf2-luc transgene did not cause a significant change in the basal expression levels of Nrf2 target genes in the liver (Fig. S1B). The data confirm that the Nrf2-luc transgene does not alter key biochemical pathways in vivo.
Acetaminophen provokes a localised hepatic Nrf2 stress response
Based on our findings in wild type mice, we administered 300 mg/kg APAP or 0.9% saline to female Nrf2-luc mice in order to monitor the Nrf2 stress response in real-time. Whilst no response was evident at 2 h post-dosing (likely due to the time required for transcription and translation of the Nrf2-luc transgene, downstream of the activation of endogenous Nrf2 signalling), in vivo imaging detected a localised bioluminescent signal consistent with the anatomical location of the liver in three of five and all APAP-treated mice at 6 and 24 h, respectively (Figs 2A,C and S2). At the latter time point, ex vivo imaging confirmed the accumulation of Nrf2-luc in the livers, but not kidneys, of all APAP-treated mice (Figs 2B,C and S2). We did not detect a bioluminescent signal in any of the saline-treated mice (Figs 2A–C and S2). The bioluminescent signals detected in the livers of APAP-treated Nrf2-luc mice ex vivo were of variable intensity (Figs 2C and S2), yet there was a significant correlation between the signal intensity and corresponding serum ALT level in the same animal (Fig. 2D), indicating that the intensity of the Nrf2-luc signal can reflect the extent of drug-induced tissue insult. Consistent with the elevated Nrf2-luc reporter activity, Taqman low density array (TLDA) analysis revealed increases in the expression levels of a range of endogenous Nrf2 target genes in the livers of APAP-treated mice 24 h post-dosing (Fig. S3). qPCR analysis confirmed the elevated expression levels of Hmox1, Gsta1 and Srxn1 under these conditions (Fig. 2E), whilst immunoblotting showed an average 14.5-fold increase (P = 0.008; Mann-Whitney U test) in the hepatic protein level of Hmox1 in Nrf2-luc mice dosed with APAP, compared to vehicle control (Fig. 2F). In keeping with the in vivo and ex vivo imaging data from Nrf2-luc mice, and in contrast to effects in the liver, there was little perturbation of endogenous Nrf2 target genes in the kidneys of APAP-treated mice 24 h post-dosing (Fig. S4). Finally, and in agreement with the serum ALT measurements, histopathological analysis of the livers of Nrf2-luc mice at 24 h post-dosing confirmed typical APAP-associated hepatic changes, i.e. coagulative necrosis and hydropic degeneration of centrilobular hepatocytes (Fig. 3), with a mean liver injury score of 1.25 (range 0–2.5). Notably, necrotic centrilobular and degenerating hepatocytes exhibited elevated expression of luciferase and Hmox1 in mice treated with APAP, but not saline (Fig. 3). Taken together, these data show that the Nrf2-luc reporter can reflect a localised hepatic stress response to APAP in vivo and ex vivo.
Cisplatin provokes a localised renal Nrf2 stress response
In order to assess the ability of the Nrf2-luc mice to report on drug-induced stress responses targeting other organs, we treated female Nrf2-luc mice with 20 mg/kg cisplatin to provoke acute kidney injury12. In line with the established time course of cisplatin nephrotoxicity, bioluminescence imaging was performed at 24, 48, 72 and 96 h after drug administration and revealed a progressive increase in bioluminescent signal consistent with the anatomical locations of the kidneys (Figs 4A,C and S5). This response was absent in saline-treated mice (Figs 4A,C and S5). Ex vivo imaging of the kidneys at 96 h post-dosing confirmed the occurrence of a kidney-specific stress response in all cisplatin-treated animals, with no bioluminescent signal detected in the livers (Figs 4B,C and S5). There was a significant correlation between the intensity of the bioluminescent signals detected in ex vivo imaging of the kidneys and blood urea nitrogen (BUN) levels (Fig. 4D), further indicating that the intensity of the Nrf2-luc signal can reflect the extent of drug-induced tissue insult. Whilst relatively small changes in the renal expression levels of endogenous Nrf2 target genes were detected 96 h post-cisplatin administration (Fig. S6), immunoblotting showed an average 8.6-fold increase (P = 0.046; unpaired t test) in the protein level of Hmox1 in the kidneys of cisplatin-treated mice (Fig. 4E). In agreement with the BUN measurements, histopathological analysis of the kidneys of Nrf2-luc mice at 96 h post-dosing confirmed typical cisplatin-induced renal changes, i.e. a variable degree of necrosis and attenuation or total loss of epithelial cells in individual to large groups of proximal tubules (Fig. 5), with a mean kidney injury score of 1.4 (range 0–3). Both luciferase and Hmox1 were expressed by epithelial cells and within the proteinaceous material in the lumen of proximal tubules that contained necrotic epithelial cells in mice treated with cisplatin, but not saline (Fig. 5). Taken together, these data show that the Nrf2-luc reporter can reflect a localised renal stress response to cisplatin in vivo and ex vivo.
Generation of albino Nrf2-luc mice
A drawback to using standard C57Bl/6 J mice as the background for studying bioluminescent reporters such as Nrf2-luc is the need to shave the black fur in order to circumvent its ability to suppress the bioluminescent signal. Moreover, standard C57Bl/6 J mice frequently exhibit localised dark skin pigmentation that can interfere with in vivo bioluminescence imaging. The impact of the latter trait was clearly demonstrated in the cisplatin study, in which several of the Nrf2-luc mice had a large area of pigmentation covering most of the dorsal skin surface (Fig. S5). In some cases the pigmentation precluded in vivo detection of the bioluminescent signal in the kidneys, despite a localised renal Nrf2-luc response being evident from ex vivo imaging (Fig. S5). To overcome these limitations and enhance the technical utility of the Nrf2-luc mice, we crossed the original line with B6(Cg)-Tyr c-2J/J (B6-albino) mice carrying a mutation in the tyrosinase gene, which results in the complete absence of pigment from hair and skin13. Following administration of the pharmacological Nrf2 activator sulforaphane, in vivo imaging demonstrated the ability to detect a bioluminescent signal without shaving in albino, but not standard, Nrf2-luc mice (Fig. S7). In the latter, a bioluminescent signal was detected only after shaving (Fig. S7). Therefore, subsequent experiments were conducted with albino Nrf2-luc mice.
The Nrf2 stress response to acetaminophen requires reactive metabolite formation
The mechanism underlying APAP hepatotoxicity in preclinical species and humans is known to involve the cytochrome P450 (CYP450) -mediated bioactivation of the parent compound to the reactive metabolite N-acetyl-p-benzoquinone imine (NAPQI), which can covalently modify cellular proteins and provoke mitochondrial dysfunction14. To ensure that the localised Nrf2-luc response to APAP reflects this toxicological mechanism, we pre-treated male albino Nrf2-luc mice with 100 mg/kg of the CYP450 inhibitor aminobenzotriazole (ABT) for 1 hour, followed by administration of 300 mg/kg APAP (Fig. 6A). As expected, ABT inhibited the development of APAP hepatotoxicity, with serum ALT levels found to be significantly lower in mice treated with ABT for 1 hour followed by APAP for 24 h, compared to those treated with APAP only (Fig. 6B). In addition, ABT almost completely abolished the histopathological changes induced by APAP in the liver (Fig. 7). Indeed, the only evidence of toxic changes were a few random necrotic hepatocytes (data not shown). Whilst in vivo (6 and 24 h) and ex vivo (24 h) imaging confirmed that APAP provoked a hepatic bioluminescent response, consistent with findings in the standard Nrf2-luc mice (Fig. 2A,B), pre-treatment with ABT abolished the APAP-induced bioluminescent signal in the livers of albino Nrf2-luc mice (Figs 6C–E and S8). In further support of this, qPCR analysis showed that ABT suppressed the ability of APAP to provoke increases in the hepatic expression levels of Nrf2 target genes (Fig. 6F), whilst the induction of Hmox1 protein by APAP was also found to be sensitive to ABT pre-treatment (Fig. 6G,H). Immunohistochemical analysis confirmed these results; in ABT pre-treated mice, Hmox1 and luciferase expression was only observed in random individual, morphologically unaltered hepatocytes, in contrast to the extensive expression detected in centrilobular hepatocytes in mice treated with APAP only (Fig. 7). Taken together, these data confirm that the Nrf2-driven response to APAP reflects the metabolism-dependent, localised insult that is known to underlie its hepatotoxicity.
The Nrf2-driven response to chemical and oxidative stress has been associated with several forms of drug toxicity in pre-clinical studies9. Amongst ongoing efforts to reduce attrition and improve the benefit:risk balance of new drugs, there is an increasing interest in using the perturbation of Nrf2 and other stress response pathways as mechanism-based markers of toxicity2. For example, amongst the Tox21 panel of cell lines is a β-lactamase reporter for the Nrf2 response (HepG2 ARE-bla)3, whilst fluorescent reporter cell lines encompassing several elements of the Nrf2 pathway have been developed through the Innovative Medicines Initiative-supported MIP-DILI consortium15. These in vitro platforms are particularly suited to high-throughput screening (HTS) of large compound libraries in the early stages of drug discovery, in which the potential of a compound to provoke an Nrf2-driven stress response can be determined, yet they cannot consider the influence of drug distribution on the likelihood of a stress response occurring in a given organ in vivo. Therefore, novel in vivo platforms that complement in vitro HTS assays and allow selected compounds to be investigated in a more holistic manner could enhance our understanding of the mechanisms and risks associated with certain toxicological traits.
In this study, consistent with the established targets of the toxicities in rodents and man, we have shown that the Nrf2 response to APAP and cisplatin is specific to the liver and kidney, respectively. Notably, cisplatin was classified as active in the Tox21 HepG2 ARE-bla assay (Fig. S9A), similar to compounds such as diethyl maleate (Fig. S9B) that we have shown to stimulate hepatic Nrf2 signalling following administration to mice10. However, we did not detect a bioluminescent response in the livers of cisplatin-treated Nrf2-luc mice, emphasizing the importance of placing in vitro findings in a whole-body context in order to confirm the occurrence and organ-specificity of the perturbation, and understand its relevance to in vivo toxicological mechanisms.
The capacity to reflect Nrf2-driven stress responses to chemically reactive metabolites represents another advantage of Nrf2-luc mice over existing in vitro reporter platforms. In man, APAP liver injury is dependent on the generation and accumulation of the electrophilic quinoneimine NAPQI14. We have previously shown that direct application of NAPQI to mouse Hepa-1c1c7 hepatoma cells triggers an Nrf2-driven stress response16, yet the relative inability of these and other immortalised liver cell lines to perform certain drug bioactivation reactions17 has rendered them unsuitable for investigating the role of reactive metabolite formation in the Nrf2 response to APAP in vitro. Here, in keeping with the zonation of the liver lobule and predisposition of centrilobular hepatocytes to generate NAPQI, we have shown that the Nrf2 stress response triggered by APAP occurs predominantly in hepatocytes around the central vein, and that pharmacological inhibition of CYP450-mediated reactive metabolite formation impedes the ability of APAP to provoke both Nrf2 activation and hepatocellular necrosis. These observations show that the Nrf2-driven stress response can reflect highly-localised, metabolism-dependent cellular perturbations associated with relevant toxicological mechanisms.
Alternative reporter mouse models for monitoring the activity of the Nrf2 pathway have been reported previously. For example, Henderson et al. generated transgenic mice expressing β-galactosidase under the transcriptional control of the mouse Hmox1 promoter, and used them to investigate the ability of non-genotoxic carcinogens to provoke oxidative stress in the liver, through post-mortem X-gal tissue staining18. Yates et al. generated mice expressing luciferase under the transcriptional control of a triplicate ARE sequence cloned from the mouse Nqo1 gene, enabling the response to triterpenoid Nrf2 activators to be visualised in vivo using bioluminescence imaging19. Taking an alternative approach, Shuhendler et al. used an injectable nanosensor to detect reactive oxygen and nitrogen species in wild type mice, through chemiluminescence and fluorescence resonance energy transfer20. Consistent with our findings, the nanosensor was used to demonstrate a reduction in APAP-induced oxidative stress in the livers of mice pre-dosed with ABT20.
In keeping with 3Rs principles, the use of real-time bioluminescent imaging to monitor Nrf2-driven stress responses allows each animal to act as its own control and enables longitudinal measurements to be taken, requiring fewer animals per study. Given the limited resolution of bioluminescence imaging, it will not always be possible to definitively assign an in vivo signal to an organ/tissue without the use of post-mortem ex vivo imaging. However, in vivo imaging can guide the decision on when, and with which tissues, to perform ex vivo analyses, and can avoid the termination of an experiment at an arbitrary time point when an Nrf2 response is clearly absent. As the proof-of-concept investigations described here have been performed with single toxic doses of APAP and cisplatin, in future studies it will be important to incorporate a range of non-toxic and toxic doses of these and other relevant compounds in order to determine the sensitivity of the Nrf2-luc reporter to subtle forms of chemical and oxidative stress that are not associated with overt organ injury. Rather than be employed as a front-line screening tool, we envisage that Nrf2 reporter mice and other emerging technologies for measuring oxidative perturbations in vivo could be used in later stages of toxicity assessment to determine the organ specificity of chemical/oxidative stress responses detected in vitro and investigate underlying toxicological mechanisms. These and other innovative approaches can contribute to the improved risk assessment of new drugs.
Unless stated otherwise, all reagents were from Sigma-Aldrich.
All animal experiments were conducted according to the UK Animals (Scientific Procedures) Act 1986 and approved by the University of Liverpool Animal Welfare Committee. Wild type C57BL/6 J mice (6–8 weeks old) were purchased from Charles River Laboratories. Nrf2-luc reporter mice11 were bred from pairs of male heterozygote and female wild type mice, and housed in a 12 h dark/light cycle in a temperature and humidity controlled, specific pathogen-free environment. Mice were fed CRM (P) diet (Special Diets Services) ad-libitum. To generate albino reporter mice, Nrf2-luc mice were backcrossed onto the B6(Cg)-Tyrc-2J/J (B6-albino) strain (Jackson Laboratory) for two consecutive generations of breeding. Genotyping of ear snips was performed by Transnetyx Inc. using a real-time PCR assay and primers specific to Firefly luciferase. For APAP studies, following overnight (16 h) fasting, mice were administered 300 mg/kg APAP or 0.9% saline (vehicle control) via intraperitoneal (IP) injection. Alternatively, mice were administered 100 mg/kg ABT or saline via IP injection 1 h prior to APAP administration. For cisplatin studies, mice were administrated 20 mg/kg cisplatin or saline via IP injection. Sulforaphane (50 mg/kg) was administered via IP injection. Following bioluminescence imaging (see below) mice were culled via exposure to increasing concentrations of carbon dioxide or via IP injection of 1000 mg/kg Pentoject (Animalcare). For each mouse, half of the right liver lobe and one entire kidney were fixed in 4% paraformaldehyde (PFA; pH 7.4) for histological examination, with the remaining liver tissue and kidney flash frozen. Blood was collected via cardiac puncture and allowed to clot for 30 min at room temperature (RT). Serum was isolated via centrifugation to enable analysis of liver and kidney injury biomarkers.
Nrf2-luc mice were imaged using an In Vivo Imaging System (IVIS) (PerkinElmer), under anaesthesia with isoflurane. Mice were injected IP with 150 mg/kg D-luciferin (Promega). After 5 min, mice were placed in the IVIS chamber and data were collected and analysed using Living Image software (Xenogen) according to the manufacturer’s instructions. Quantification of luminescence signals was achieved using the Region of Interest (ROI) function within Living Image software. Within a single experiment, an area was drawn around the broadest signal and used for all other animals in that experiment. Total flux within the ROI was considered as the signal intensity. For ex vivo imaging, mice were culled, tissues excised and immersed in 300 µg/mL D-Luciferin and analysed using the IVIS platform. For quantification of ex vivo luminescence signals, an area was drawn around the dish containing the tissue.
Alanine aminotransferase assay
Serum ALT levels were measured using Infinity ALT Liquid Stable Reagent (Thermo Fisher Scientific), according to the manufacturer’s instructions.
Total GSH levels were measured in liver tissues as previously described21.
Blood urea nitrogen assay
Serum BUN levels were measured using a Quantichrom Urea Assay kit (BioAssay Systems), according to the manufacturer’s instructions.
Histology and immunohistochemistry
After PFA fixation for 24–48 h, liver and kidney specimens were trimmed and routinely embedded in paraffin wax. Consecutive sections (3–5 µm) were prepared and routinely stained with haematoxylin and eosin (HE), underwent the Period Acid Schiff (PAS) reaction, or were subjected to immunohistochemical staining. For immunohistochemistry, an autostainer (Dako) was used. Briefly, sections were dewaxed, dehydrated and subjected to antigen retrieval (20 min incubation at 98 °C in citrate buffer, pH 6 for Hmox1, and in EDTA buffer, pH 9 for luciferase). After incubation with the primary antibodies (mouse anti-Hmox1, MA1-112, Thermo Fisher Scientific; mouse anti-firefly luciferase, ab16466, Abcam) for 1 h at RT and blocking of endogenous peroxidase (peroxidase block; Dako) for 10 min at RT, sections were incubated for 30 min at RT with the detection system (Envision System HPR Mouse; Dako), followed by incubation with diaminobenzidine as chromogen and counterstaining with haematoxylin. Liver and kidney injury were assessed using previously reported histopathological scoring systems22,23. All histological and immunohistochemical specimens were examined by a veterinary pathologist (AK) who was blinded to the treatment of the animals.
Taqman low-density array analysis
TLDA cards containing probes for established Nrf2 target genes were generated by Applied Biosystems. A pool of all samples was used as a calibrator across cards, with individual gene expression levels normalised to the housekeeping gene 18 S ribosomal RNA. Analysis was performed on an ABI ViiA 7 Thermocycler, as previously described7.
cDNA synthesis and qPCR analysis
Total RNA was extracted from 30 mg of tissue using an RNeasy Mini Kit (Qiagen). RNA quantity and purity were determined using a Nanodrop 1000 Spectrometer (Thermo Fisher Scientific). RNA was reverse transcribed to cDNA using GoScript Reverse Transcription System (Promega) according to the manufacturer’s instructions. qPCR analysis was performed using Power SYBR Green (Thermo Fisher Scientific) on an ABI ViiA 7 Thermocycler (Applied Biosystems) according to the manufacturer’s instructions. Primer sequences for mouse Hmox1, Gsta1, Srxn1, Nqo1 and Gapdh are detailed in Supplementary Table 1. For each sample, the average threshold cycle (Ct) value was normalized to Gapdh and the relevant control sample, using the formula 2−∆∆Ct.
Western blot analysis
Western blot analysis of Nrf2 targets in liver or kidney tissues was performed as previously described24. Uncropped blots are provided in Fig. S10. The Hmox1 (ab13243), Nqo1 (ab2346) and β-actin (ab6276) antibodies were from Abcam. Band intensities were quantified using ImageJ.
Pearson’s R correlations and associated P values were calculated using the R software package hmisc25,26. All other statistical analyses were performed using GraphPad Prism 5.0 (GraphPad Software). Differences were considered significant at P < 0.05.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This work was supported by the EU-EFPIA Innovative Medicines Initiative as part of the MIP-DILI project (grant number 115336) and an award from the University of Liverpool Technology Directorate Voucher Scheme. We wish to thank the staff of the Histology Laboratories, Veterinary Laboratory Services, Department of Veterinary Pathology and Public Health, Institute of Veterinary Sciences, University of Liverpool, and the Laboratory for Animal Model Pathology, Institute of Veterinary Pathology, Vetsuisse Faculty, University of Zurich, for excellent technical assistance. We thank Lynn McLaughlin and colleagues at the University of Liverpool Biomedical Services Unit for help generating the albino Nrf2-luc mice.